68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients

Launched by PEKING UNION MEDICAL COLLEGE HOSPITAL · Sep 18, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging technique called 68Ga-RM26-RGD PET/CT, which is designed to help doctors see certain types of tumors more clearly in patients with breast cancer, prostate cancer, or brain tumors. The researchers want to find out if this new imaging agent can improve the detection of tumors by targeting specific receptors that are often found on cancer cells. The goal is to see if this method can be useful in diagnosing and monitoring these cancers.

To participate in the trial, patients need to be between the ages of 65 and 74 and have confirmed or suspected breast, brain, or prostate cancer. They should have had a specific type of PET/CT scan within the last two weeks and must agree to participate by signing a consent form. However, pregnant or breastfeeding individuals and those with certain medical conditions may not be eligible. Participants in the trial can expect to undergo imaging tests that will help assess the effectiveness of this new approach in visualizing their tumors.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patients with confirmed or suspected breast/brain/prostate cancer;
• • 68Ga-RM26-RGD and 18F-FDG(or 68Ga-RM26 or 68Ga-RGD) PET/CT within 2 week;
• • signed written consent.
• Exclusion Criteria:
• • pregnancy;
• • breastfeeding;
• • any medical condition that in the opinion of the investigator may significantly interfere with study compliance.